Financials in USD. Standardized financial statements.
A compact view of how Metagenomi, Inc. Common Stock turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue? | $25.21M | $52.30M | $44.76M | $17.20M | $243,000 |
| Revenue Growth? | -51.8% | +16.8% | +160.2% | +6978.2% | 0.0% |
| Cost of Revenue? | $5.32M | $0 | $94.40M | $1.73M | $387,000 |
| Gross Profit? | $19.89M | $52.30M | -$49.65M | $15.47M | -$144,000 |
| Gross Margin? | +78.9% | +100.0% | -110.9% | +89.9% | -59.3% |
| Operating Expenses? | $115.91M | $141.20M | $28.84M | $60.11M | $23.80M |
| Operating Income? | -$96.01M | -$88.90M | -$78.49M | -$44.64M | -$23.95M |
| EBITDA? | -$90.70M | -$83.49M | -$74.28M | -$39.19M | -$20.75M |
| Income Before Tax | -$87.93M | -$83.57M | -$60.23M | -$41.02M | -$21.44M |
| Income Tax Expense | -$58,000 | -$5.51M | $8.03M | $2.57M | $0 |
| Net Income? | -$87.87M | -$78.06M | -$68.25M | -$43.59M | -$21.44M |
| EPS? | $-2.36 | $-2.09 | $-1.82 | $-1.16 | $-3.62 |
| Diluted EPS? | $-2.36 | $-2.09 | $-1.82 | $-1.16 | $-3.62 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality